Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|16|2457-2463

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.16, 2014-08, pp. : 2457-2463

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Octreotide long‐acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population‐based analysis

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 2039-2049

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites

By  

Oncology, Vol. 82, Iss. 6, 2012-05 ,pp. : 315-320

Karger

Access to resources Recommend Favorite

A Double-Blind, Parallel-Group Study of Amlodipine versus Long-Acting Nitrate in the Management of Elderly Patients with Stable Angina

By  

Cardiology, Vol. 96, Iss. 2, 2001-12 ,pp. : 72-77

Karger

Access to resources Recommend Favorite

Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer

By  

Oncology, Vol. 87, Iss. 2, 2014-07 ,pp. : 104-113

Karger

Access to resources Recommend Favorite

Oxaliplatin in Combination with Infusional 5-Fluorouracil and Leucovorin Every 2 Weeks as First-Line Treatment in Patients with Advanced Colorectal Cancer: A Phase II Study

By  

Oncology, Vol. 61, Iss. 1, 2001-07 ,pp. : 36-41

Karger

Access to resources Recommend Favorite